Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 87.15
+1.90 (2.23%)
Nov 12, 2025, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
2.02M HKD
Profits / Employee
200.45K HKD
Market Cap
146.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | 3,279 | 1,297 | 65.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| WuXi Biologics | 12,575 |
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Akeso | 3,035 |
| WuXi XDC Cayman | 2,041 |
Innovent Biologics News
- 2 days ago - Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting - PRNewsWire
- 7 days ago - Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting - PRNewsWire
- 12 days ago - Innovent's License Deal Fails To Excite investors - Benzinga
- 16 days ago - China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study - Reuters
- 16 days ago - Innovent Biologics' Mazdutide Surpasses Semaglutide In HbA1c And Weight Loss In Phase 3 Trial - Nasdaq
- 16 days ago - Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 - PRNewsWire
- 20 days ago - Market Today: Innovent and Takeda's $11.4B Deal Boosts Biotech Sector - GuruFocus
- 21 days ago - Innovent Biologics (IVBIY) and Takeda Partner for $11.4 Billion Cancer Therapy Deal - GuruFocus